DEXCOM, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 124.3 USD | -9.91% |
|
-4.87% | +0.20% |
| Apr. 26 | Wall Street: the worst week of 2024 is followed by the best | CF |
| Apr. 26 | Morgan Stanley Adjusts DexCom's Price Target to $132 From $122 | MT |
Presenter SpeechJeffrey Johnson (Analysts)All right. Good morning. Why don't we get started? M...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
DexCom, Inc. specializes in the design, manufacture and marketing of continuous glucose monitoring (CGM) systems for people with diabetes and healthcare providers. The company provides an implantable device for continuous measurement of blood glucose levels and an external transmitter to which the sensor transmits glucose levels at specified intervals.
The United States accounts for 72.5% of net sales.
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
124.3
USD
Average target price
150
USD
Spread / Average Target
+20.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +0.20% | 54.66B | |
| -2.31% | 185B | |
| -3.20% | 105B | |
| -5.04% | 66.59B | |
| +17.29% | 47.78B | |
| +4.06% | 41.26B | |
| +2.36% | 26.95B | |
| +2.07% | 26.37B | |
| +12.96% | 24.8B | |
| -1.93% | 24.6B |
- Stock Market
- Equities
- DXCM Stock
- News DexCom, Inc.
- Transcript : DexCom, Inc. Presents at Baird 2022 Global Healthcare Conference, Sep-14-2022 08
